H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on TScan Therapeutics today and set a price target of $7.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising potential of TScan Therapeutics’ TSC-101 treatment. The recent data from the Phase 1 ALLOHA trial demonstrated encouraging results, showcasing favorable relapse-free and overall survival rates in patients treated with TSC-101 compared to the control group. The treatment’s efficacy is further supported by its performance in patients with poor prognostic genetic mutations, such as TP53, where it showed a capacity to prevent relapse.
Moreover, the company has improved its manufacturing process, reducing the time required and potentially enhancing clinical outcomes by addressing issues related to mixed chimerism and relapse. The FDA’s acceptance of TScan’s trial design and statistical analysis plan further de-risks the path toward registration, indicating regulatory support. These developments, coupled with the treatment’s tolerability and lack of severe adverse effects, reinforce the analyst’s confidence in the potential success of TSC-101 in future trials and its commercial viability.